Find Clinical Trial

Evaluation of the effect of the oral administration of perindopril orodispersible at a dose of 0.150 mg/kg/day on the muscular and myocardial function in early stage Duchenne muscular dystrophy. Double blind two years study, randomised versus placebo


← Back
Study Phase

Phase 3

Therapeutic Area

Cardiovascular Diseases

IndicationMuscular disease
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

PERINDOPRIL ARGININE,
S090652

Active Substance CodeS090652
Protocol CodeCL3-90652-004
EudraCT Code2008-003856-32


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility